Abstract
Implementation of therapy for acute kidney injury (AKI) depends on successful prediction of individual patient prognosis. Clinical markers as serum creatinine (sCr) have limitations in sensitivity and early response. The aim of the study was to identify novel molecules in urine which show altered levels in response to AKI and investigate their value as predictors of recovery. Changes in the urinary proteome were here investigated in a cohort of 88 subjects (55 AKI patients and 33 healthy donors) grouped in discovery and validation independent cohorts. Patients’ urine was collected at three time points: within the first 48 h after diagnosis(T1), at 7 days of follow-up(T2) and at discharge of Nephrology(T3). Differential gel electrophoresis was performed and data were confirmed by Western blot (WB), liquid chromatography/mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA). Retinol binding protein 4 (RBP4) and kininogen-1 (KNG1) were found significantly altered following AKI. RBP4 increased at T1, and progressively decreased towards normalization. Maintained decrease was observed for KNG1 from T1. Individual patient response along time revealed RBP4 responds to recovery earlier than sCr. In conclusion, KNG1 and RBP4 respond to AKI. By monitoring RBP4, patient’s recovery can be anticipated pointing to a role of RBP4 in prognosis evaluation.
Highlights
Acute kidney injury (AKI) is a multifactorial syndrome, a frequent clinical complication in hospitalized patients and responsible of a substantial morbidity and mortality[1,2]
Urinary Retinol binding protein 4 (RBP4) and KNG1 proteins are identified as main responders to acute kidney injury (AKI)
The opposite trend was observed for KNG1, decreasing its urinary concentration in response to AKI from the first time point evaluated (T1)
Summary
Acute kidney injury (AKI) is a multifactorial syndrome, a frequent clinical complication in hospitalized patients and responsible of a substantial morbidity and mortality[1,2]. A substantial proportion of AKI patients in daily clinical practice have underlying CKD In this context, design of novel therapeutic strategies aimed at limiting kidney injury and preventing AKI progression requires novel biomarkers that allow early monitoring of kidney damage and helping in prognosis prediction[3,4]. Our group have investigated urine in the search for novel molecular targets of potential use in the clinical setting from a diagnosis or prognosis point of view in the context of diabetic nephropathy[7], chronic kidney disease[8], and cardiovascular disease[9]. Molecular alterations in urine in response to AKI in the search for novel indicators Their capability to monitor recovery from AKI and predict patient’s prognosis will be evaluated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.